A comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers

Histopathology

Volumn 65, Issue 6, 2014, Pages 868-878

  Koh, Jaemoon ^a,b   Go, Heounjeong ^c   Kim, Moon Young ^a,b   Jeon, Yoon Kyung ^a,b   Chung, Jin Haeng ^b,d   Chung, Doo Hyun ^a,b  

^a Seoul National University Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c University of Ulsan College of Medicine   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

Algorithm; Biopsy specimens; Histologic subtyping; Immunohistochemistry; Napsin A and p40 panel; Non small cell carcinoma; TTF 1

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; MUCIN; NAPSIN A; PROTEIN P40; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ALGORITHM; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DECISION TREE; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG SURGERY; MACHINE LEARNING; MAJOR CLINICAL STUDY; MALE; NON SMALL CELL LUNG CANCER; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; TISSUE MICROARRAY; BIOPSY; CLASSIFICATION; LUNG TUMOR; PATHOLOGY; SUPPORT VECTOR MACHINE;

ALGORITHMS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DECISION TREES; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINES; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84919452117     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/his.12507     Document Type: Article

References (34)

1. Shaw AT, Yeap BY, Mino-Kenudson M et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J. Clin. Oncol. 2009; 27; 4247-4253.
2. Lynch TJ, Bell DW, Sordella R et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 2004; 350; 2129-2139.
3. Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 2005; 353; 123-132.
4. Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304; 1497-1500.
5. Herbst RS, Johnson DH, Mininberg E et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J. Clin. Oncol. 2005; 23; 2544-2555.
6. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006; 355; 2542-2550.
7. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J. Clin. Oncol. 2008; 26; 3543-3551.
8. Scagliotti G, Hanna N, Fossella F et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14; 253-263.
9. Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am. J. Surg. Pathol. 2010; 34; 1805-1811.
10. Warth A, Muley T, Herpel E et al. Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology 2012; 61; 1017-1025.
11. Pelosi G, Rossi G, Bianchi F et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J. Thorac. Oncol. 2011; 6; 1039-1049.
12. Travis WD, Brambilla E, Noguchi M et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J. Thorac. Oncol. 2011; 6; 244-285.
13. Rekhtman N, Ang DC, Sima CS, Travis WD, Moreira AL. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod. Pathol. 2011; 24; 1348-1359.
14. Loo PS, Thomas SC, Nicolson MC, Fyfe MN, Kerr KM. Subtyping of undifferentiated non-small cell carcinomas in bronchial biopsy specimens. J. Thorac. Oncol. 2010; 5; 442-447.
15. Travis WD, World Health Organization, International Agency for Research on Cancer, International Association for the Study of Lung Cancer, International Academy of Pathology. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon, Oxford: IARC Press, Oxford University Press (distributor), 2004; 344.
16. Edwards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J. Clin. Pathol. 2000; 53; 537-540.
17. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am. J. Surg. Pathol. 2011; 35; 15-25.
18. Rossi G, Pelosi G, Barbareschi M, Graziano P, Cavazza A, Papotti M. Subtyping non-small cell lung cancer: relevant issues and operative recommendations for the best pathology practice. Int J Surg Pathol 2013; 21; 326-336.
19. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch. Pathol. Lab. Med. 2012; 136; 163-171.
20. Whithaus K, Fukuoka J, Prihoda TJ, Jagirdar J. Evaluation of napsin A, cytokeratin 5/6, p63, and thyroid transcription factor 1 in adenocarcinoma versus squamous cell carcinoma of the lung. Arch. Pathol. Lab. Med. 2012; 136; 155-162.
21. Krishnan VG, Westhead DR. A comparative study of machine-learning methods to predict the effects of single nucleotide polymorphisms on protein function. Bioinformatics 2003; 19; 2199-2209.
22. Cruz JA, Wishart DS. Applications of machine learning in cancer prediction and prognosis. Cancer Inform 2006; 2; 59-77.
23. Nicholson AG, Gonzalez D, Shah P et al. Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis. J. Thorac. Oncol. 2010; 5; 436-441.
24. Righi L, Graziano P, Fornari A et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer 2011; 117; 3416-3423.
25. da Cunha Santos G, Lai SW, Saieg MA et al. Cyto-histologic agreement in pathologic subtyping of non small cell lung carcinoma: review of 602 fine needle aspirates with follow-up surgical specimens over a nine year period and analysis of factors underlying failure to subtype. Lung Cancer 2012; 77; 501-506.
26. Azzoli CG, Baker S Jr, Temin S et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J. Clin. Oncol. 2009; 27; 6251-6266.
27. Bishop JA, Teruya-Feldstein J, Westra WH, Pelosi G, Travis WD, Rekhtman N. p40 (DeltaNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod. Pathol. 2012; 25; 405-415.
28. Nobre AR, Albergaria A, Schmitt F. p40: a p63 isoform useful for lung cancer diagnosis - a review of the physiological and pathological role of p63. Acta Cytol. 2013; 57; 1-8.
29. Butnor KJ, Burchette JL. p40 (DeltaNp63) and keratin 34betaE12 provide greater diagnostic accuracy than p63 in the evaluation of small cell lung carcinoma in small biopsy samples. Hum. Pathol. 2013; 44; 1479-1486.
30. Pelosi G, Fabbri A, Bianchi F et al. DeltaNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J. Thorac. Oncol. 2012; 7; 281-290.
31. Vogt AP, Cohen C, Siddiqui MT. p40 (DeltaNp63) is more specific than p63 and cytokeratin 5 in identifying squamous cell carcinoma of bronchopulmonary origin: a Review and Comparative Analysis. Diagn. Cytopathol. 2014; 42; 453-458.
32. Au NH, Gown AM, Cheang M et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl. Immunohistochem. Mol. Morphol. 2004; 12; 240-247.
33. Wang BY, Gil J, Kaufman D, Gan L, Kohtz DS, Burstein DE. P63 in pulmonary epithelium, pulmonary squamous neoplasms, and other pulmonary tumors. Hum. Pathol. 2002; 33; 921-926.
34. Pelosi G, Pasini F, Olsen Stenholm C et al. p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol 2002; 198; 100-109.